top of page

Prof. Zachary T. Bloomgarden


Dr. Bloomgarden is a clinician in private practice with an international reputation for writing and lecturing on diabetes, having authored more than 550 articles. He is Clinical Professor in the Department of Medicine of the Icahn School of Medicine at Mount Sinai, and is Editor of the Journal of Diabetes.  He served on the Board of the American Association of Clinical Endocrinologists, the Journals Managing Subcommittee of the Endocrine Society, and the Editorial Board of Diabetes Care, has been principal investigator in numerous studies, and is a reviewer for many journals, including Diabetes Care, Endocrine Practice, the Journal of Clinical Endocrinology and Metabolism, the Medical Letter on Drugs and Therapeutics, the Lancet, Lancet Diabetes and Endocrinology, JAMA Internal Medicine, the Annals of Internal Medicine, BMC Cardiovascular Disorders, BMJ Open Diabetes Research & Care, Arteriosclerosis, Thrombosis, and Vascular Biology, the Journal of the American College of Cardiology, the American Journal of Epidemiology, and Pediatrics.  In 2012, Dr. Bloomgarden was awarded the title of Master of the American College of Endocrinology.  He has been listed for many years in the “Castle Connolly Guide: The Best Doctors New York Metro Area.”  


Dr Bloomgarden’s interests span the overall field of diabetes.  He has carefully followed the development of therapeutic approaches over the past two decades, and for many years wrote a renowned monthly commentary in Diabetes Care, entitled “Perspectives on the News," focusing on this and other aspects of clinical care. 


Currently, as the Editor of the Journal of Diabetes, he writes frequent commentaries addressing various aspects of treatment.  He is interested in the epidemiology of diabetes with particular focus on cardiovascular disease, and has paid particular attention to questions of safety of therapeutic approaches and, even more important, to the potential for cardiovascular and microvascular benefit of diabetes treatment.  He also is a frequent commentator on novel treatment approaches including insulin treatment modalities, incretin-based treatments, and inhibitors of glucose transport.

bottom of page